Minireviews
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jun 16, 2022; 10(17): 5541-5550
Published online Jun 16, 2022. doi: 10.12998/wjcc.v10.i17.5541
Ethical review of off-label drugs during the COVID-19 pandemic
Qiu-Yu Li, Ye Lv, Zhuo-Yu An, Ni-Ni Dai, Xue Hong, Yu Zhang, Li-Jun Liang
Qiu-Yu Li, Ni-Ni Dai, Department of Pulmonary and Critical Care Medicine, Peking University Third Hospital, Beijing 100191, China
Ye Lv, Advanced Institute for Medical Sciences, Dalian Medical University, Dalian 116044, Liaoning Province, China
Zhuo-Yu An, Peking University Institute of Hematology, Peking University People’s Hospital, Beijing 100191, China
Xue Hong, Yu Zhang, Li-Jun Liang, Department of Ethics Office, Peking University Third Hospital, Beijing 100191, China
Author contributions: Li QY and Lv Y contributed equally to this paper; Li QY and Ye L reviewed the literature and contributed to manuscript drafting and revising; An ZY, Dai NN, Hong X, Zhang Y and Liang LJ contributed to making a revision to the manuscript; Li QY also contributed to conceptualization, methodology, and funding acquisition; and All authors issued final approval for the version to be submitted.
Supported by National Natural Science Foundation of China, No. 81900641; Peking University Health Center for Combating the Pandemic Programs, No. BMU 2021MX020, and No. BMU 2022MX008.
Conflict-of-interest statement: There is no conflict of interests to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qiu-Yu Li, MD, Doctor, Department of Pulmonary and Critical Care Medicine, Peking University Third Hospital, No. 49 Huayuan North Road, Haidian District, Beijing 100191, China. liqiuyu00@bjmu.edu.cn
Received: February 7, 2022
Peer-review started: February 7, 2022
First decision: March 22, 2022
Revised: March 26, 2022
Accepted: April 9, 2022
Article in press: April 9, 2022
Published online: June 16, 2022
Processing time: 121 Days and 21.8 Hours
Core Tip

Core Tip: High-quality scientific research is very important in the attempt to effectively control the coronavirus disease 2019 epidemic and ensure people’s life health and safety. Chloroquine and hydroxychloroquine have received much attention.